Julian Baker’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-670,751
| Closed | -$26.6M | – | 88 |
|
|
2026
Q1 | $26.6M | Hold |
670,751
| – | – | 0.15% | 45 |
|
|
2025
Q4 | $16.8M | Buy |
+670,751
| New | +$17M | 0.1% | 58 |
|
|
2025
Q2 | – | Sell |
-1,227,178
| Closed | -$17.6M | – | 90 |
|
|
2025
Q1 | $17.6M | Hold |
1,227,178
| – | – | 0.2% | 36 |
|
|
2024
Q4 | $20.6M | Hold |
1,227,178
| – | – | 0.22% | 42 |
|
|
2024
Q3 | $19.6M | Buy |
1,227,178
+677,966
| +123% | +$8.31M | 0.2% | 42 |
|
|
2024
Q2 | $4.96M | Buy |
+549,212
| New | +$5.21M | 0.06% | 65 |
|
|
2022
Q3 | – | Sell |
-1,127,273
| Closed | -$5.49M | – | 118 |
|
|
2022
Q2 | $5.49M | Hold |
1,127,273
| – | – | 0.03% | 79 |
|
|
2022
Q1 | $10.1M | Hold |
1,127,273
| – | – | 0.06% | 67 |
|
|
2021
Q4 | $12.7M | Hold |
1,127,273
| – | – | 0.06% | 71 |
|
|
2021
Q3 | $18.8M | Buy |
1,127,273
+727,273
| +182% | +$15.1M | 0.08% | 65 |
|
|
2021
Q2 | $8.88M | Buy |
+400,000
| New | +$9.4M | 0.04% | 79 |
|
Julian Baker's CNTA Position: Q2 2026 in Review
Julian Baker sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 670,751 shares — an estimated $26.6M sold.
Julian Baker first reported a position in CNTA in Q2 2021 and held it in 11 quarters. The position peaked at $26.6M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Julian Baker reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Julian Baker sold 670,751 Centessa Pharmaceuticals shares in Q2 2026, an estimated $26.6M.
- Julian Baker first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 11 quarters.
- Julian Baker's Centessa Pharmaceuticals position peaked at $26.6M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.